I
ImmunArray
A molecular diagnostics company
About ImmunArray
ImmunArray is a clinically driven company specializing in molecular diagnostic tests designed to support the diagnosis and prognosis of complex medical conditions. The company primarily serves healthcare providers, including rheumatologists and neurologists, by offering innovative diagnostic solutions. Operating in the medical diagnostics market, ImmunArray focuses on developing assays and multiplex tests that enhance patient triage and treatment decisions. Their flagship product, 'Talk to Us,' is a diagnostic test that helps rule out Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. Additionally, their BRAINBox program aims to improve the diagnosis and prognosis of brain injuries, including both acute traumatic brain injury (TBI) and chronic phases.
Read full description
ImmunArray's business model revolves around the development and commercialization of these diagnostic tests, generating revenue through the sale of test kits and related services to healthcare institutions. The company collaborates with various partners and stakeholders in the healthcare sector to advance its research and product offerings.
At a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Rehovot, Israel
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Testing, Biotechnology, Neurology, Autoimmune, Degenerative Diseases, Spinout, Hospital, IVD, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2016 | $10M | $40M | Exigent Capital | ↗ |
| SPINOUTOther financing | Jan 2006 | $0 | — | Weizmann Institute of Science | — |
Growth signals
Latest recorded traffic for ImmunArray is 50 monthly website visits, down 75% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Exigent Capital
Other known investors2 additional known investors
Weizmann Institute of Science
Johns Hopkins Technology Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ImmunArray on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImmunArray’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.